Books

Borer JS, Isom OW (Editors and authors).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II.  Advances in Cardiology, 2004: 41: 1-190, Karger (Basel).
Borer JS.

Contemporary Diagnosis and Management of Valvular Heart Diseases, Handbooks in Health Care, Newtown PA (2003), 277 pp.

Borer JS, Isom OW (Eds.).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II, Advances in Cardiology, 2002; 39:1-217, Karger (Basel).

Borer JS, Somberg J. (eds and authors) Cardiovascular Drug Development  Marcel Dekker, (New York), 1999.

Journal Articles & Book Chapters

Borer JS, LeHeuzey Y. Characterization of the heart rate lowering action of ivabradine, a selective If current inhibitor. American Journal of Therapeutics, 2007, in review

Borer JS. If inhibition in challenging cardiac conditions: evidence and future prospects. Medicographia 2007; in press.

Borer JS. Cellular and molecular basis of myocardial dysfunction in valvular heart diseases: implications for therapeutic decisions. Hjerteforum 2007, in press.

Borer JS. Heart rate and ischemic heart disease, in Heart Rate Management (Benetos A, ed), Wolters Kluwer Health (Paris), 2007, in press.

Borer JS. Angiotensin converting enzyme (ACE) inhibition: a landmark advance in treatment for cardiovascular diseases. European Heart Journal 2007; invited, in press.

Borer JS. Indications for operation for aortic regurgitation in asymptomatic patients in Harrison’s Online (Harrison’s Principles of Internal Medicine on line updates, Cardiovascular Disease) (Braunwald E, ed), McGraw-Hill (New York), 2007 (5/4/07), www.harrisonline.com (www.accessmedicine.com), pp. 1-7.

Truter SL, Catanzaro DF, Borer JS, Lee E, Gupta A, Supino PG,  Carter J, Herrold EM, Huang Z, Pitlor LL, Dumlao TF. Extracellular matrix remodeling in aortic regurgitation: role of mitogen-activated protein kinases. JACC, in review 2007

Borer JS, Supino PG. Radionuclide angiography part ii: equilibrium imaging in Nuclear Cardiac Imaging: Principles and Applications, 4th Edition (Iskandrian A, ed), Oxford, New York, 2007, in press.

Friedewald V, Bonow RO, Borer JS, Carabello BA, Kleine P, Akins C, Roberts WC
The Editor’s roundtable: cardiac valve surgery. American Journal of Cardiology 2007; 99:1269-1278.

Borer JS. Supino PG, A new course on hypothesis and protocol development. Medical Education 2007; 41:525-526.

Borer JS, Herrold EM, Carter JN, Catanzaro DF, Supino P. Cellular and molecular basis of remodelling in valvular heart diseases. Heart Failure Clinics 2006; 2: 415-424.

Supino PG, Borer JS, Schuleri K, Gupta A, Hochreiter C, Kligfield P, Herrold EM, Preibisz J, Bomsztyk M. Exercise tolerance but not ST segment response to exercise predicts event-free survival in asymptomatic chronic non-ischemic mitral regurgitation. American Journal of Cardiology 2007, in press.

Borer, Jeffrey S. Borer, MD; Hubert Pouleur, MD, PhD; Eric Abadie, MD; Ferrenc Follath, MD; Janet Wittes, PhD; Raymond J. Lipicky, MD; Marc A. Pfeffer, MD, PhD; Bertram Pitt, MD; Faiez Zannad, MD, PhD Assessment of cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart Journal 2007 in press.

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Similarities and Differences in Design Considerations for Cell Therapy and Pharmacologic Cardiovascular Clinical Trials. Cardiology 2007, in press.

Supino PG, Borer JS. Epidemiology of valvular heart diseases: a growing public health problem. Heart Failure Clinics 2006; 2:379-393.

Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Yu F, Southard E, Lee LY,  Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites.Circulation Research 2007, in review.

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez-Sendon JL, Steg PG, Tardif J-C, Tavazzi L, Tendera M. Resting heart rate: a forgotten factor in cardiovascular disease? Journal of the American College of Cardiology 2007, in press.

White WB, West CR, Borer JS, Gorelick PS, Lavange LM, Pan SX, Weiner E, Verburg K.Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. American Journal of Cardiology 2007, 99:91-98.

Sasson L, Ureche A, Manolache G, Ciubotaru A, Borer JS, Schachner A. Nitric oxide synthase inhibitor (MTR-105) during open heart surgery: a double blind placebo controlled study of hemodynamic effect and safety. Chest, 2007, in review.

Fox KM, Ferrari R, Yusuf S, Borer, JS. Should ACE inhibitors be used to improve outcome in patients with coronary disease and preserved LV function? European Heart Journal 2006; 27:2154-2157.

Borer JS. Therapeutic effects of If blockade: evidence and perspective. Pharmacological Research 2006; 53:440-446.

Corbett JR, Akinboboye OO, Bacharach SL, Borer JS, Botvinick EH, DePuey EG, Ficaro EP, Hansen CL, Henzlova MJ, Van Kriekinge S. Equilibrium radionulide angiocardiography. Journal of Nuclear Cardiology 2006; 13:e56-79.

Borer JS. Can Ifinhibition help in angina? Dialogues in Cardiovascular Medicine 2006; 11:21-29.

Borer JS. Cyclo-oxygenase inhibition: what should we do to resolve the confusion? An American Perspective. Journal of Cardiovascular Pharmacology, 2006; 47(Suppl. 1):S87-S91. 

Borer JS. Clinical effect of “pure” heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine. Advances in Cardiology, 2006, 43:54-64.